Scientists at MIT developed antibody-bottlebrush conjugates (ABCs), a novel cancer therapy platform that vastly increases drug-to-antibody ratios compared to traditional antibody-drug conjugates (ADCs). ABCs covalently link antibodies to molecular bottlebrush prodrugs, allowing hundreds of drug molecules per antibody, including standard cytotoxins and lower-potency chemotherapies. This method aims to enhance tumor targeting while reducing systemic toxicity. The flexibility in conjugation chemistry and payload selection may overcome current ADC limitations, potentially enabling safer and more effective targeted oncology treatments.